Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression

Inclusion Criteria: * Histologic or cytologic diagnosis of NSCLC, Stage IIIB/IV. * Males or females between 18 Years to 75 Years. * No prior cisplatin-based chemotherapy, if the surgery or radiotherapy has been administered, the interval is at least above four weeks. The interval for targeted therapy such as EGFR TKI is above 2 weeks. * Performance status of 0, 1 on the ECOG criteria. Expected survival is above three months. * At least one unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST. 2000). * Patients can have the brain / meningeal metastasis history, but the metastasis must be treated by operation or radiotherapy), and clinically stable for at least 2 months. * Adequate hematologic (neutrophil count \>= 1,500/uL, platelets \>= 100,000/uL), hepatic (transaminase =\< upper normal limit(UNL)x2.5, bilirubin level =\< UNLx1.5), and renal (creatinine =\< UNL) function. * Patient compliance that allow adequate follow-up. Informed consent from patient or patient's relative. * APE1 IHC (++ or +++). * If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[IUD\], birth control pills, or barrier device) during and for 2 months after trial. If male, use of an approved contraceptive method during the study and 2 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment. * No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole. Exclusion Criteria: * Inability to comply with protocol or study procedures. * Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Pregnant or breast-feeding. * Enrollment in other study within 30 days. * Brain metastasis with symptoms. * Hypokalemic periodic paralysis history.